The shares of Piramal Pharma Limited were trading at ₹244.98 down by ₹10.86 or 4.24 per cent on the NSE today at 12.05 pm.
Piramal Pharma Limited reported strong financial results for Q2 and H1 FY25, ending September 30, 2024, with a consolidated revenue growth of 17 per cent year-on-year to ₹2,242 crore. This surge was largely driven by the robust performance of its Contract Development and Manufacturing Organization (CDMO) segment, which rose 24 per cent year-on-year (YoY).
- Also read: Piramal Pharma Q2 net profit jumps over 4-fold to ₹23 crore; revenue at ₹2,242 crore
The company’s EBITDA increased 28 per cent YoY to ₹403 crore, improving its EBITDA margin to 18 per cent, up from 16 per cent in Q2 FY24. This rise reflects strategic cost optimizations and a favorable revenue mix. Additionally, net profit after tax soared by 350 per cent YoY to ₹23 crore, benefiting from strong operational efficiency and strategic initiatives.
Piramal Pharma’s CDMO business led the growth with increased demand for generic APIs and a $80 million expansion at its Lexington facility, aimed at doubling sterile fill-finish capabilities by FY27. Meanwhile, the Complex Hospital Generics (CHG) segment saw a 9 per cent increase in revenue, supported by rising demand for inhalation anesthesia products in the US and emerging markets, along with ongoing capacity expansions at Dahej and Digwal.
- Also read: Piramal Pharma to invest $80 million in Kentucky facility expansion
CEO Nandini Piramal emphasized the firm’s long-term target of achieving $2 billion in revenue and a 25 per cent EBITDA margin by FY30, leveraging expansion plans and increasing focus on differentiated and specialty products.
